⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for PAXG Out in the Country

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PAXG Out in the Country

Official Title: PAXG Out in the Country

Study ID: NCT04480268

Study Description

Brief Summary: The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

Detailed Description: Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal malignancies, with a 5-year overall survival (OS) rate for all stages combined lower than 10%, decreasing to 3% in advanced disease. Additionally, PDAC is expected to become the 2nd leading cause for cancer-related death by 2030. Chemotherapy still represents the only therapeutic option in most cases, since 70% of PDAC patients exhibit metastatic or locally advanced disease at diagnosis. Concerning metastatic PDAC patients, combination chemotherapy has resulted in improved survival compared with single-agent treatment. Based on promising phase I/II studies, the PAXG regimen (cisplatin, nab-paclitaxel, capecitabine and gemcitabine) has been recommended for first-line treatment of metastatic PDAC patients in the 2019 edition of Associazione Italiana Oncologia Medica (AIOM) guidelines. Also, this regimen was approved by the Agenzia Italiana del Farmaco (AIFA) as first therapy of borderline-resectable, locally advanced and metastatic PDAC patients with good performance status (ECOG 0-1) and age 18-75 years. Description of the intervention (schedule of visits): All PDAC patients who are treated with PAXG regimen as first-line/primary chemotherapy at the participating institutions from January 1st 2020 to December 31st 2020 according to inclusion and exclusion criteria will be included in the present study. Power size calculation: The sample size will be as large as possible with a competitive enrollment. All patients treated by the PAXG regimen during 2020 in the participating institutions will be included into the trial. The investigators hypothesize that at least 175 patients (60% metastatic and 40% non-metastatic) from about 30 Italian centers will be enrolled by the end of the year. Such a sample size, or a larger one, will allow to compute in both groups a 95% confident interval of the 1-year OS with at least 10% margin of error, assuming to observe a (target) 1-year OS of 60% for metastatic patients and of 80% for non-metastatic. The trial will be considered successful if the target 1-year OS will fall into the corresponding computed 95% CI.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

IRCCS Centro di Riferimento Oncologico (CRO), Aviano, , Italy

Istituto dei tumori Giovanni Paolo II, Bari, , Italy

AULSS 1 di Belluno, Belluno, , Italy

ASST Papa Giovanni XXIII, Bergamo, , Italy

Azienda Ospedaliera Policlinico Sant'Orsola-Malpighi, Bologna, , Italy

Azienda Ospedaliera AOU di Cagliari, Cagliari, , Italy

Ospedale di Carpi, Carpi, , Italy

USL Toscana Nord Ovest, Carrara, , Italy

Fondazione Istituto Giglio, Cefalù, , Italy

Ospedaliera Sant' Anna di Como Asst Lariana, Como, , Italy

Azienda Ospedaliera Universitaria Ospedali Riuniti di Foggia, Foggia, , Italy

ASST Rhodense, Garbagnate, , Italy

Ospedale Moriggia Pelascini, Gravedona, , Italy

Ospedale Generale Provinciale di Macerata, Macerata, , Italy

Irccs Irst, Meldola, , Italy

ASST Melegnano e Della Martesana, Melegnano, , Italy

IRCCS San Raffaele Medical Oncology Unit, Milan, , Italy

Istituto Oncologico Veneto IRCCS, Padova, , Italy

Ospedale Civico di Palermo, Palermo, , Italy

Azienda Ospedaliera di Parma, Parma, , Italy

Azienda Ospedaliera di Piacenza, Piacenza, , Italy

Giovanni Paolo II-Maria Paternò, Ragusa, , Italy

Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi D'Aragona, Salerno, , Italy

AULSS 4 Veneto Orientale, San Donà Di Piave, , Italy

IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, , Italy

Azienda Ospedaliera Ordine Mauriziano, Torino, , Italy

Presidio Ospedaliero Molinette, Torino, , Italy

Azienda Sanitaria Universitaria Integrata, Udine, , Italy

ASST Sette Laghi, Varese, , Italy

Ospedale San Bortolo Azienda ULSS8 Berica-Distretto Est, Vicenza, , Italy

Contact Details

Name: Michele Reni, MD

Affiliation: IRCCS Ospedale San Raffaele

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: